{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:33:18Z","timestamp":1784086398307,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Advanced liver fibrosis can lead to cirrhosis, resulting in an accelerated risk of hepatocellular carcinoma and liver failure. Fuzheng Huayu formula (FZHY) is a traditional Chinese medicine formula treated liver fibrosis in China approved by a Chinese State Food and Drug Administration (NO: Z20050546), composed of\n                    <jats:italic>Salvia Miltiorrhiza<\/jats:italic>\n                    bge.,\n                    <jats:italic>Prunus davidiana<\/jats:italic>\n                    (Carr.) Franch., cultured\n                    <jats:italic>Cordyceps sinensis<\/jats:italic>\n                    (BerK.) Sacc. Mycelia,\n                    <jats:italic>Schisandra chinensis<\/jats:italic>\n                    (Turcz.) Baill.,\n                    <jats:italic>Pinus massoniana<\/jats:italic>\n                    Lamb., and\n                    <jats:italic>Gynostemma pentaphyllum<\/jats:italic>\n                    (Thunb.) Makino. However, the main active substances and mechanism of FZHY are unclear. The aim of this study is to identify a novel anti-fibrotic compound, which consists of the main active ingredients of FZHY, and investigate its mechanism of pharmacological action. The main active ingredients of FZHY were investigated by quantitative analysis of FZHY extracts and FZHY-treated plasma and liver in rats. The anti-fibrotic composition of the main active ingredients was studied through uniform design\n                    <jats:italic>in vivo<\/jats:italic>\n                    , and its mechanism was evaluated in carbon tetrachloride (CCl\n                    <jats:sub>4<\/jats:sub>\n                    )- and bile duct ligation (BDL)-induced liver fibrosis models in rats and mice, and transforming growth factor beta 1-induced LX-2 cell activation model\n                    <jats:italic>in vitro<\/jats:italic>\n                    . A novel Chinese medicine, namely JY5 formula, consisting of salvianolic acid B, schisantherin A, and amygdalin, the main active ingredients of FZHY, significantly alleviated hepatic hydroxyproline content and collagen deposition in CCl\n                    <jats:sub>4<\/jats:sub>\n                    -and BDL-induced fibrotic liver in rats and mice. In addition, JY5 inhibited the activation of hepatic stellate cells (HSCs) by inactivating Notch signaling\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . In this study, we found a novel JY5 formula, which exerted anti-hepatic fibrotic effects by inhibiting the Notch signaling pathway, consequently suppressing HSCs activation. These results provide an adequate scientific basis for clinical research and application of the JY5 formula, which may be a potential novel therapeutic candidate for liver fibrosis.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.671152","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T02:34:48Z","timestamp":1632278088000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["The Novel Chinese Medicine JY5 Formula Alleviates Hepatic Fibrosis by Inhibiting the Notch Signaling Pathway"],"prefix":"10.3389","volume":"12","author":[{"given":"Yadong","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenggang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiamei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom9100608","article-title":"The Roles of Notch Signaling in Liver Development and Disease","volume":"9","author":"Adams","year":"2019","journal-title":"Biomolecules"},{"key":"B2","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10616-019-00329-y","article-title":"TGF-\u03b21 Signaling Activates Hepatic Stellate Cells through Notch Pathway","volume":"71","author":"Aimaiti","year":"2019","journal-title":"Cytotechnology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"108846","DOI":"10.1016\/j.biopha.2019.108846","article-title":"The Effect and Mechanisms of Fuzheng Huayu Formula against Chronic Liver Diseases","volume":"114","author":"Chen","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e46512","DOI":"10.1371\/journal.pone.0046512","article-title":"Inhibition of Notch Signaling by a \u03b3-secretase Inhibitor Attenuates Hepatic Fibrosis in Rats","volume":"7","author":"Chen","year":"2012","journal-title":"PLoS One"},{"key":"B5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1172\/JCI93562","article-title":"The Balancing Act of the Liver: Tissue Regeneration versus Fibrosis","volume":"128","author":"Cordero-Espinoza","year":"2018","journal-title":"J. Clin. Invest."},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jaut.2013.07.008","article-title":"STAT3-mediated Attenuation of CCl4-Induced Mouse Liver Fibrosis by the Protein Kinase Inhibitor Sorafenib","volume":"46","author":"Deng","year":"2013","journal-title":"J. Autoimmun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0070-2153(10)92003-6","article-title":"Canonical and Non-canonical Notch Ligands","volume":"92","author":"D\u2019Souza","year":"2010","journal-title":"Curr. Top. Dev. Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1159\/000374098","article-title":"Hepatic Fibrosis: Emerging Therapies","volume":"33","author":"Friedman","year":"2015","journal-title":"Dig. Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/hep.27394","article-title":"Myeloid-specific Disruption of Recombination Signal Binding Protein J\u03ba Ameliorates Hepatic Fibrosis by Attenuating Inflammation through Cylindromatosis in Mice","volume":"61","author":"He","year":"2015","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11418-020-01394-w","article-title":"The Effects of Inhibiting the Activation of Hepatic Stellate Cells by Lignan Components from the Fruits of Schisandra Chinensis and the Mechanism of Schisanhenol","volume":"74","author":"He","year":"2020","journal-title":"J. Nat. Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"C499","DOI":"10.1111\/1750-3841.12415","article-title":"Transformation of Salvianolic Acid B to Salvianolic Acid a in Aqueous Solution and the In Vitro Liver Protective Effect of the Main Products","volume":"79","author":"Kan","year":"2014","journal-title":"J. Food Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.phymed.2018.09.010","article-title":"Systematically Identifying the Hepatoprotective Ingredients of Schisandra Lignan Extract from Pharmacokinetic and Pharmacodynamic Perspectives","volume":"53","author":"Kang","year":"2019","journal-title":"Phytomedicine"},{"key":"B13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11523-017-0484-7","article-title":"Sorafenib: A Review in Hepatocellular Carcinoma","volume":"12","author":"Keating","year":"2017","journal-title":"Target. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of Liver Fibrosis: a Translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"B15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.coph.2019.09.006","article-title":"New and Emerging Anti-fibrotic Therapeutics Entering or Already in Clinical Trials in Chronic Liver Diseases","volume":"49","author":"Lemoinne","year":"2019","journal-title":"Curr. Opin. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1749-8546-4-12","article-title":"Effect of Fuzheng Huayu Formula and its Actions against Liver Fibrosis","volume":"4","author":"Liu","year":"2009","journal-title":"Chin. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.3892\/etm.2018.5886","article-title":"Influence of Amygdalin on PDG, IGF and PDGFR Expression in HSC-T6 Cells","volume":"15","author":"Luo","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s13273-016-0031-0","article-title":"Amygdalin Inhibits HSC-T6 Cell Proliferation and Fibrosis through the Regulation of TGF-\u03b2\/CTGF","volume":"12","author":"Luo","year":"2016","journal-title":"Mol. Cell. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejphar.2018.02.051","article-title":"Novel Insights on Notch Signaling Pathways in Liver Fibrosis","volume":"826","author":"Ni","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1152\/physrev.00005.2017","article-title":"Notch Signaling in Development, Tissue Homeostasis, and Disease","volume":"97","author":"Siebel","year":"2017","journal-title":"Physiol. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"60778","DOI":"10.18632\/oncotarget.18484","article-title":"Reversal Effect of Jagged1 Signaling Inhibition on CCl4-Induced Hepatic Fibrosis in Rats","volume":"8","author":"Tang","year":"2017","journal-title":"Oncotarget"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1177\/1535370213498979","article-title":"Salvianolic Acid B Inhibits Hepatic Stellate Cell Activation through Transforming Growth Factor Beta-1 Signal Transduction Pathway In Vivo and In Vitro","volume":"238","author":"Tao","year":"2013","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.2147\/DDDT.S194787","article-title":"Salvianolic Acid A Attenuates CCl4-Induced Liver Fibrosis by Regulating the PI3K\/AKT\/mTOR, Bcl-2\/Bax and Caspase-3\/cleaved Caspase-3 Signaling Pathways","volume":"13","author":"Wang","year":"2019","journal-title":"Drug Des. Devel Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jep.2012.09.048","article-title":"Inhibitory Effects of Salvianolic Acid B on CCl4-Induced Hepatic Fibrosis through Regulating NF-\u039ab\/i\u03bab\u03b1 Signaling","volume":"144","author":"Wang","year":"2012","journal-title":"J. Ethnopharmacology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1258\/ebm.2009.009293","article-title":"Salvianolic Acid B Attenuates Hepatocyte Apoptosis by Regulating Mediators in Death Receptor and Mitochondrial Pathways","volume":"235","author":"Yan","year":"2010","journal-title":"Exp. Biol. Med. (Maywood)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.3748\/wjg.v23.i29.5333","article-title":"Salvianolic Acid B Protects Hepatocytes from H2O2 Injury by Stabilizing the Lysosomal Membrane","volume":"23","author":"Yan","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1055\/s-0036-1571295","article-title":"Antifibrotic Therapies: Where Are We Now?","volume":"36","author":"Yoon","year":"2016","journal-title":"Semin. Liver Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jhep.2014.03.009","article-title":"Traditional Chinese Medicine (TCM) for Fibrotic Liver Disease: hope and Hype","volume":"61","author":"Zhang","year":"2014","journal-title":"J. Hepatol."},{"key":"B29","first-page":"4130","article-title":"Myofibroblastic Transformation of Rat Hepatic Stellate Cells: the Role of Notch Signaling and Epithelial-Mesenchymal Transition Regulation","volume":"19","author":"Zhang","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/labinvest.2015.149","article-title":"Inhibition of Notch Signaling Pathway Prevents Cholestatic Liver Fibrosis by Decreasing the Differentiation of Hepatic Progenitor Cells into Cholangiocytes","volume":"96","author":"Zhang","year":"2016","journal-title":"Lab. Invest."}],"updated-by":[{"DOI":"10.3389\/fphar.2026.1854159","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000}}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.671152\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:08:49Z","timestamp":1779106129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.671152\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":30,"alternative-id":["10.3389\/fphar.2021.671152"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.671152","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]},"article-number":"671152"}}